Explore

Trendline Trendline
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
Trendline Trendline
Jazz Pharmaceuticals Acquires Actio Biosciences to Enhance Epilepsy Treatment Portfolio

Jazz Pharmaceuticals Acquires Actio Biosciences to Enhance Epilepsy Treatment Portfolio

Jazz Pharmaceuticals Acquires Actio Biosciences to Enhance Epilepsy Treatment Portfolio
Trendline Trendline
Jazz Pharmaceuticals Expands Epilepsy Portfolio with $1.3 Billion Actio Acquisition

Jazz Pharmaceuticals Expands Epilepsy Portfolio with $1.3 Billion Actio Acquisition

Jazz Pharmaceuticals Expands Epilepsy Portfolio with $1.3 Billion Actio Acquisition
Trendline Trendline
Mineralys Therapeutics Reports Financial Results and Prepares for Lorundrostat Launch

Mineralys Therapeutics Reports Financial Results and Prepares for Lorundrostat Launch

Mineralys Therapeutics Reports Financial Results and Prepares for Lorundrostat Launch
Trendline Trendline
BridgeBio Reports Strong Q2 2026 Financial Results and Advances in Drug Development

BridgeBio Reports Strong Q2 2026 Financial Results and Advances in Drug Development

BridgeBio Reports Strong Q2 2026 Financial Results and Advances in Drug Development
Trendline Trendline
Johnson Johnson's FDA Approval for OTTAVA and Talc Settlement Impact Shareholders

Johnson Johnson's FDA Approval for OTTAVA and Talc Settlement Impact Shareholders

Johnson Johnson's FDA Approval for OTTAVA and Talc Settlement Impact Shareholders
Trendline Trendline
Sanofi Faces Drug Shortages Amid Manufacturing Issues at Irish Facility

Sanofi Faces Drug Shortages Amid Manufacturing Issues at Irish Facility

Sanofi Faces Drug Shortages Amid Manufacturing Issues at Irish Facility
Trendline Trendline
Axsome Therapeutics Reports Strong Financial Growth and New Product Launches in Q2 2026

Axsome Therapeutics Reports Strong Financial Growth and New Product Launches in Q2 2026

Axsome Therapeutics Reports Strong Financial Growth and New Product Launches in Q2 2026
Trendline Trendline
Axsome Therapeutics Reports Significant Growth in Second Quarter 2026 with New Alzheimer's Treatment

Axsome Therapeutics Reports Significant Growth in Second Quarter 2026 with New Alzheimer's Treatment

Axsome Therapeutics Reports Significant Growth in Second Quarter 2026 with New Alzheimer's Treatment
Trendline Trendline
Hanwha's $1.2 Billion Bid for Austal USA Could Reshape U.S. Naval Shipbuilding

Hanwha's $1.2 Billion Bid for Austal USA Could Reshape U.S. Naval Shipbuilding

Hanwha's $1.2 Billion Bid for Austal USA Could Reshape U.S. Naval Shipbuilding
Trendline Trendline
Ceribell Secures New Credit Facility and Reports Strong Q2 2026 Financial Results

Ceribell Secures New Credit Facility and Reports Strong Q2 2026 Financial Results

Ceribell Secures New Credit Facility and Reports Strong Q2 2026 Financial Results
Trendline Trendline
Novartis UK Precision Medicine Director Role Focuses on Biomarker Strategies

Novartis UK Precision Medicine Director Role Focuses on Biomarker Strategies

Novartis UK Precision Medicine Director Role Focuses on Biomarker Strategies